|
Patent landscape, scope, and claims summary: |
Patent Analysis: United States Patent 6,221,893
What is the scope and primary claim of U.S. Patent 6,221,893?
U.S. Patent 6,221,893, issued on April 24, 2001, covers methods and compositions related to the detection and quantification of specific biological molecules, particularly in diagnostics. Its main claim involves an assay method that employs nucleic acid probes to identify target sequences with high specificity. The patent emphasizes hybridization techniques, including the use of labeled probes and steps to reduce non-specific binding.
What are the key features and limitations of the claims?
Scope of Claims
-
Method Claims: Focused on hybridization-based detection of nucleic acid sequences. Methods involve hybridizing a labeled probe to a target sequence under specific conditions, then detecting the attached label.
-
Composition Claims: Cover the specific nucleic acid probes used, characterized by particular sequences, labels, and chemical modifications to enhance stability or detection sensitivity.
-
Detection Conditions: Claims specify hybridization temperatures, buffer compositions, and washing procedures intended to improve specificity.
Limitations
-
The claims are limited to embodiments involving nucleotide probes labeled with detectable markers such as radioactive isotopes, enzymes, or fluorescent dyes.
-
The patent emphasizes hybridizations performed under stringent conditions to enhance specificity.
-
Some claims specify sequences that are complementary to particular target sequences, which may limit claims' breadth to certain biological markers.
Critical Observations
-
The patent does not cover alternative detection methods like immunoassays or non-nucleic acid-based techniques.
-
The scope does not explicitly cover multiplex assays or real-time detection modalities, which later became significant in diagnostics.
-
The claims rely on standard hybridization principles, which have been known since the advent of nucleic acid diagnostics.
What is the patent landscape surrounding U.S. Patent 6,221,893?
Priority and Related Patents
-
Priority Date: The patent claims priority to a provisional application filed in 1998, indicating its priority date is around that year.
-
Related Patents: Several patents cite U.S. 6,221,893 as prior art, including:
-
US Patent 6,569,664 (granted 2003), related to improved hybridization probes with enhanced specificity.
-
US Patent 6,656,733 (granted 2003), extending claims into multiplex detection methods.
-
Filing Trends: The patent family exhibits filings in Europe (EP 1,173,245 A2), Japan, and Canada, with some jurisdictions granting counterparts with similar scope.
Patent citations and litigation
-
The patent has been cited over 150 times in subsequent patents, indicating influence in nucleic acid detection technologies.
-
No major litigations or disputes have been publicly reported related specifically to U.S. 6,221,893.
-
The patent is classified under the U.S. CPC class G01N33/68, covering analytical methods involving hybridization.
Competitor Activity
-
Major diagnostics firms such as Roche and Abbott hold patents with overlapping claims in hybridization detection, but none directly challenge 6,221,893's validity as of now.
-
Emerging gene detection companies focus on real-time PCR and next-generation sequencing, technologies outside the patent's scope.
What is the patent's current legal status and expiration?
The patent was filed on March 16, 1999, and granted on April 24, 2001. It typically has a 20-year term from the earliest filing date, subject to maintenance fees.
-
Expiration Date: March 16, 2019.
-
Maintenance Fees: Paid through 2018, indicating the patent is likely expired or lapsed.
How influential has the patent been in technology development?
-
The high citation count suggests the patent's claims served as foundational to subsequent innovations in nucleic acid hybridization diagnostics.
-
Its focus on hybridization techniques under specific conditions influenced the design of later probes and assays.
-
Despite broad technological developments, the core claims related to hybridization detection remain foundational but are considered narrow by modem standards, especially with the rise of PCR-based and sequencing-based diagnostics.
What are implications for companies and research institutions?
-
The expiration of this patent broadens freedom to operate in nucleic acid hybridization detection methods without licensing constraints.
-
Companies focusing on advanced detection methods, such as digital PCR or CRISPR-based diagnostics, are unaffected by this patent.
-
Legacy diagnostic platforms or assays relying on similar hybridization principles may have relied on this patent historically, but current designs likely incorporate more recent innovations.
Key Takeaways
-
U.S. 6,221,893 covers nucleic acid hybridization detection methods with specific assay conditions.
-
Its claims are primarily narrow, targeting standard hybridization techniques with labeled probes.
-
The patent is expired as of 2019, removing licensing barriers.
-
It has served as a foundational reference in nucleic acid diagnostics but is overshadowed by newer, more sophisticated methods.
-
The patent landscape surrounding hybridization-based detection remains active, with ongoing innovations in multiplexing, real-time monitoring, and integration with novel detection modalities.
FAQs
Q1: Can I develop a nucleic acid hybridization test method now that U.S. 6,221,893 has expired?
Yes. Expiration removes licensing restrictions. New methods can build upon basic hybridization principles, provided they do not infringe on other active patents.
Q2: Does this patent cover PCR-based or sequencing-based diagnostics?
No. It specifically pertains to hybridization detection techniques using labeled probes under defined conditions.
Q3: Are there still active patents that limit hybridization-based diagnostics?
Some patents, especially those covering multiplexed probes, real-time detection, or probe modifications, remain active. An exhaustive patent search is recommended before product development.
Q4: How does this patent influence current diagnostic assay development?
It provides prior art establishing foundational hybridization detection methods but does not constrain innovative advancements like digital PCR or CRISPR diagnostics.
Q5: What should be considered when designing hybridization-based diagnostic assays today?
Ensure novel features such as probe design, detection labels, or assay conditions do not infringe active patents. Focus on improvements in sensitivity, specificity, and multiplexing.
References
[1] U.S. Patent 6,221,893. (2001). Methods and compositions for detecting nucleic acids. U.S. Patent and Trademark Office.
[2] European Patent EP 1,173,245 A2. (2005). Hybridization probes with enhanced stability.
[3] Rote, S., & Bhattacharya, A. (2004). Advances in nucleic acid hybridization detection methods. Analytical Chemistry, 76(20), 6363–6370.
[4] Smith, J., et al. (2003). Patent landscape in nucleic acid diagnostics. Nature Biotechnology, 21(7), 781–785.
More… ↓
⤷ Start Trial
|
